Nasus Pharma files initial beneficial ownership statement for CFO Nir Sassi
NSRX•Nasus Pharma CFO Nir Sassi disclosed options to buy 115,000 ordinary shares in an initial beneficial ownership statement.
1. Options disclosed
Nir Sassi disclosed options to buy 115,000 ordinary shares in an initial beneficial ownership statement.




